HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Dec 2013 07:00 AM
RNS
Blocklisting Six Monthly Return
23 Dec 2013 04:31 PM
PRN
Director Share Dealings
18 Dec 2013 09:02 AM
RNS
Sinopharm distribution joint venture in China
16 Oct 2013 11:58 AM
RNS
Director/PDMR Shareholding
09 Oct 2013 07:00 AM
RNS
Payment From Janssen Pharmaceuticals
09 Oct 2013 07:00 AM
RNS
Lilly Deal for Fruquintinib
09 Oct 2013 07:00 AM
RNS
Analyst & Investor Briefing
03 Oct 2013 07:00 AM
RNS
Analyst briefing on Chi-Med's R&D business
13 Sep 2013 02:21 PM
RNS
Holding(s) in Company
08 Aug 2013 12:05 PM
RNS
Director/PDMR Shareholding
30 Jul 2013 07:00 AM
RNS
Interim Results
17 Jul 2013 07:00 AM
RNS
Global Phase III HPML-004 maintenance study starts
01 Jul 2013 07:00 AM
RNS
Blocklisting Interim Review
25 Jun 2013 07:00 AM
RNS
Volitinib Phase I triggers US$5 million milestone
24 Jun 2013 07:00 AM
RNS
Notice of Results
10 May 2013 12:24 PM
RNS
Result of AGM
24 Apr 2013 07:00 AM
RNS
Global Phase III UC trial initiated with HPML-004
12 Apr 2013 07:16 AM
RNS
Nutrition Science Partners JV Approved
09 Apr 2013 07:00 AM
RNS
2012 Annual Report and Notice of AGM
08 Apr 2013 07:00 AM
RNS
Data Presentations at AACR
26 Mar 2013 07:00 AM
RNS
Final Results
28 Feb 2013 07:00 AM
RNS
Total Voting Rights
18 Feb 2013 07:00 AM
RNS
Notice of Results
28 Jan 2013 11:15 AM
RNS
Holding(s) in Company
31 Dec 2012 07:00 AM
RNS
Blocklisting Six Monthly Return
28 Nov 2012 07:00 AM
RNS
Chi-Med and Nestle? Health Science Joint Venture
01 Nov 2012 07:00 AM
RNS
Phase I trial with EGFR inhibitor theliatinib
08 Oct 2012 07:00 AM
RNS
TR1 Notification of major interest in shares
28 Sep 2012 01:42 PM
RNS
Total Voting Rights
13 Sep 2012 02:16 PM
RNS
Director's Shareholding
28 Aug 2012 11:21 AM
RNS
Change of Nominated Adviser
31 Jul 2012 07:00 AM
RNS
Interim Results
05 Jul 2012 09:08 AM
RNS
Total Voting Rights
29 Jun 2012 07:00 AM
RNS
Blocklisting Interim Review
28 Jun 2012 07:00 AM
RNS
Notice of Results
14 Jun 2012 01:33 PM
RNS
Exercise of Options
06 Jun 2012 07:00 AM
RNS
Anti-Cancer Clinical Data Presented at ASCO
30 May 2012 01:48 PM
RNS
Director/PDMR Shareholding
11 May 2012 12:32 PM
RNS
Result of AGM
10 Apr 2012 07:00 AM
RNS
2011 Annual Report and Notice of AGM
20 Mar 2012 07:00 AM
RNS
Final Results
22 Feb 2012 07:00 AM
RNS
Novel c-Met inhibitor Volitinib Enters the Clinic
20 Feb 2012 07:00 AM
RNS
Notice of Results
14 Feb 2012 08:07 AM
RNS
Holding(s) in Company
02 Feb 2012 07:00 AM
RNS
Total Voting Rights
05 Jan 2012 10:49 AM
RNS
Holding(s) in Company
29 Dec 2011 07:00 AM
RNS
Blocklisting Six Monthly Return
21 Dec 2011 07:00 AM
RNS
CANCER THERAPY COLLABORATION WITH ASTRAZENECA
12 Dec 2011 07:00 AM
RNS
Chi-Med Loan Facility
04 Nov 2011 07:00 AM
RNS
Initiates Epitinib Phase I clinical study

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings